

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC: <https://www.coronavirus.gov>.

Get the latest research from NIH: <https://www.nih.gov/coronavirus>.

Find NCBI SARS-CoV-2 literature, sequence, and clinical content: <https://www.ncbi.nlm.nih.gov/sars-cov-2/>.

FULL TEXT LINKS



*Auton Autacoid Pharmacol.* 2013 Oct;33(3-4):43-8. doi: 10.1111/aap.12010. Epub 2013 Aug 2.

# Sodium molybdate prevents hypertension and vascular prostanoid imbalance in fructose-overloaded rats

H A Peredo <sup>1</sup>, V Andrade, A S Donoso, H J Lee, A M Puyó

Affiliations

## Affiliation

<sup>1</sup> Cátedra de Anatomía Humana (macro y microscópica) and INFIBIOC, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires; CONICET, Junín 956, 1113, Buenos Aires, Argentina.

PMID: 23906370 DOI: [10.1111/aap.12010](https://doi.org/10.1111/aap.12010)

## Abstract

(1) Fructose (F) overload produces elevated blood pressure (BP), hyperglycaemia, hypertriglyceridemia and insulin resistance, resembling human metabolic syndrome. Previously, we found altered vascular prostanoid (PR) production in this model. (2) Sodium molybdate (Mo), as well as sodium tungstate, causes insulin-like effects and normalizes plasma glucose levels in streptozotocin-treated diabetic rats. We studied the effects of Mo on BP, metabolic parameters and release of PR from the mesenteric vascular bed (MVB) in F-overloaded rats. (3) Four groups of male Sprague-Dawley rats were analysed: Control, tap water to drink; F, F solution 10% W/V to drink; C<sub>Mo</sub>, Mo 100 mg kg day<sup>-1</sup> and F<sub>Mo</sub>, both treatments. After 9 weeks, the animals were killed and MVBs removed and the released PRs measured. (4) F increased BP, glycemia, triglyceridemia and insulinemia. Mo treatment prevented the increases in BP and glycemia, but did not modify triglyceridemia or insulinemia. In addition, Mo decreased BP in controls. (5) Prostaglandins (PG) F<sub>2</sub> alpha and E<sub>2</sub>, PG 6-ketoF<sub>1</sub> alpha and thromboxane (TX) B<sub>2</sub>, as well as inactive metabolites of prostacyclin (PGI<sub>2</sub>) and TXA<sub>2</sub> were detected. F decreased the production of vasodilator PRs PGI<sub>2</sub> and PGE<sub>2</sub> in MVB. Mo prevented these alterations and increased PGE<sub>2</sub> in controls. Vasoconstrictor PRs PGF<sub>2</sub> alpha and TXA<sub>2</sub> release was not modified. (6) Mo treatment, beyond its known lowering effect on glycemia, prevents the reduction in the vascular release of vasodilator PR observed in this model. This could be one of the mechanisms by which Mo avoids the increase in BP caused by F overload in the rat.

**Keywords:** fructose; hypertension; metabolic syndrome; molybdate; prostanoids.

© 2013 John Wiley & Sons Ltd.

## Related information

[MedGen](#)

[PubChem Compound \(MeSH Keyword\)](#)

## LinkOut - more resources

[Full Text Sources](#)

[Wiley](#)

**Medical**

[MedlinePlus Health Information](#)

**Research Materials**

[NCI CPTC Antibody Characterization Program](#)

**Miscellaneous**

[NCI CPTAC Assay Portal](#)